Kinetic and immunohistochemical characteristics of mitogen-induced cutaneous hypersensitivity in chickens selected for antibody responsiveness.
Mitogen-induced cutaneous hypersensitivity was evaluated in chickens selected for high and low antibody responses to SRBC, and in a random bred control line. Wing web swelling responses were found after subcutaneous administration of phytohemagglutinin (PHA), concanavalin A (Con A), pokeweed mitogen (PWM), and Escherichia coli lipopolysaccharide (LPS), respectively, in all three lines. All mitogens induced significant acute 4 h wing web swelling responses, followed by a significant (classical) late 24 h wing web swelling response. The 4 h responses were significantly lower in the L line, whereas a tendency for lower responses at 24 h in the L line was found as well. Immunohistochemical evaluation of the early and late wing web swelling responses revealed extravascular localisation of leukocytes at 24 h after sensitization with mitogens, which consisted of CD4+ cells, CD8+ cells, TCR-1+ cells, and heterophils, but no B cells, whereas the 4 h swelling response was primarily characterized by oedema. Cutaneous hypersensitivity either initiated by T-cell mitogens as well as B-cell mitogens may depend for an important part on the rapid induction of local homing of lymphocytes towards the sensitizing agent, which may be mediated by an acute local expression of molecules with chemo-attractive capacities. Interpretation of cellular immunity responses in vivo such as delayed-type hypersensitivity should therefore incorporate oedema-initiating characteristics of sensitizing agents. The relationship between the magnitude of cutaneous hypersensitivity to mitogens and selection for antibody responsiveness is discussed.
Parmentier
H K
HK
Department of Animal Sciences, Agricultural University, Wageningen, The Netherlands. henk.parmentier@genr@vh.wau.nl
De Vries Reilingh
G
G
Nieuwland
M G
MG
D000818:Animals; D000917:Antibody Formation; D002645:Chickens / Q000276:immunology*; D003208:Concanavalin A / Q000008:administration & dosage / Q000276:immunology; D003876:Dermatitis, Atopic / Q000276:immunology / Q000473:pathology / Q000662:veterinary*; D007150:Immunohistochemistry; D007279:Injections, Subcutaneous; D007700:Kinetics; D008070:Lipopolysaccharides / Q000008:administration & dosage / Q000276:immunology; D008934:Mitogens / Q000008:administration & dosage / Q000276:immunology*; D010835:Phytohemagglutinins / Q000008:administration & dosage / Q000276:immunology; D011043:Pokeweed Mitogens / Q000008:administration & dosage / Q000276:immunology; D012867:Skin / Q000187:drug effects / Q000276:immunology / Q000473:pathology
D008070:Lipopolysaccharides; D008934:Mitogens; D010835:Phytohemagglutinins; D011043:Pokeweed Mitogens; D003208:Concanavalin A